Estrella Immunopharma, Inc. (ESLA) stock forecast & analysis
0.5352
NasdaqCM · USDDelayed by 15 minutes
Up: +0.2173, +68.4%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.3100
- Previous close
- 0.3179
- Day range
- 0.3033 – 0.8500
- 52-week range
- 0.2950 – 3.15
- Volume (shares)
- 61.47M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 43.50M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 0.93
- Market cap
- 23.28M
Market Scanner’s AI analysis of Estrella Immunopharma, Inc. (ESLA), updated October 2026: Estrella Immunopharma's STARLIGHT-1 trial advances, alongside mixed technical indicators and persistent net losses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Estrella Immunopharma, Inc. (ESLA) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Estrella Immunopharma's STARLIGHT-1 trial advances, alongside mixed technical indicators and persistent net losses.
Recent analyses for Estrella Immunopharma (ESLA) covered the advancement of its STARLIGHT-1 clinical trial, including patient treatment and site activation. The reports also detailed the company's ongoing net losses and negative shareholder equity, alongside mixed technical indicators such as moving averages suggesting a downtrend, while MFI indicated buying pressure.
ESLA news & sentiment
News coverage highlighted the advancement of Estrella Immunopharma's STARLIGHT-1 clinical trial, including patient treatment and site activation. Social media discussions were not covered in the provided notes.
ESLA technical picture
The stock's price is below its 50-day and 200-day simple moving averages, indicating a downtrend. Momentum readings are neutral, but MACD suggests bearish momentum, while MFI points to strong buying pressure.
Fundamentals
Estrella Immunopharma has consistently reported net losses and negative operating income across its fiscal years and the most recent quarter. The company's balance sheet shows negative total shareholder equity, continuing a negative trend.
Factors discussed — upside
- STARLIGHT-1 clinical trial treating first patient in dose-expansion phase
- Activation of multiple clinical trial sites
- Money Flow Index (MFI) indicating strong buying pressure
Factors discussed — risks
- Consistent net losses reported across fiscal years and recent quarter
- Negative total shareholder equity
- 10-day EMA below 50-day SMA, and 50-day SMA below 200-day SMA
- MACD below zero indicating bearish momentum
- Clinical trial progress
- Financial performance
- Technical indicators
- Biotechnology industry
Summary updated .
ESLA technical indicators
Common technical indicators for ESLA, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.59 | Price below |
| 10-day exponential moving average | 0.41 | Price above |
| Relative strength index (14-day) | 55.60 | Neutral |
| MACD line (12/26/9) | -0.0594 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.32 – 0.56 | Price inside the bands |
Analyses
Recent ESLA.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-16 ESLA.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Estrella Immunopharma, Inc.?
- The bull case for Estrella Immunopharma centers on progress in its STARLIGHT-1 clinical trial, with the treatment of the first patient in the dose-expansion phase and the activation of multiple clinical sites indicating forward momentum. Additionally, the Money Flow Index has shown strong buying pressure.
- What are the risks for Estrella Immunopharma, Inc.?
- Risks for Estrella Immunopharma include persistent net losses and negative shareholder equity, alongside technical indicators such as moving averages suggesting a downtrend and bearish momentum reflected in the MACD.
- Is Estrella Immunopharma, Inc. bullish or bearish?
- Recent AI analyses of Estrella Immunopharma, Inc. examined factors on both sides. Discussed upside: The bull case for Estrella Immunopharma centers on progress in its STARLIGHT-1 clinical trial, with the treatment of the first patient in the dose-expansion phase and the activation of multiple clinical sites indicating forward momentum. Additionally, the Money Flow Index has shown strong buying pressure. Discussed risks: Risks for Estrella Immunopharma include persistent net losses and negative shareholder equity, alongside technical indicators such as moving averages suggesting a downtrend and bearish momentum reflected in the MACD. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Estrella Immunopharma, Inc.?
- News coverage highlighted the advancement of Estrella Immunopharma's STARLIGHT-1 clinical trial, including patient treatment and site activation. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse Estrella Immunopharma, Inc.?
- Every analysis of Estrella Immunopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Estrella Immunopharma, Inc.?
The bull case for Estrella Immunopharma centers on progress in its STARLIGHT-1 clinical trial, with the treatment of the first patient in the dose-expansion phase and the activation of multiple clinical sites indicating forward momentum. Additionally, the Money Flow Index has shown strong buying pressure.
What are the risks for Estrella Immunopharma, Inc.?
Risks for Estrella Immunopharma include persistent net losses and negative shareholder equity, alongside technical indicators such as moving averages suggesting a downtrend and bearish momentum reflected in the MACD.
Is Estrella Immunopharma, Inc. bullish or bearish?
Recent AI analyses of Estrella Immunopharma, Inc. examined factors on both sides. Discussed upside: The bull case for Estrella Immunopharma centers on progress in its STARLIGHT-1 clinical trial, with the treatment of the first patient in the dose-expansion phase and the activation of multiple clinical sites indicating forward momentum. Additionally, the Money Flow Index has shown strong buying pressure. Discussed risks: Risks for Estrella Immunopharma include persistent net losses and negative shareholder equity, alongside technical indicators such as moving averages suggesting a downtrend and bearish momentum reflected in the MACD. These are descriptive observations, not a recommendation.
What is the latest sentiment on Estrella Immunopharma, Inc.?
News coverage highlighted the advancement of Estrella Immunopharma's STARLIGHT-1 clinical trial, including patient treatment and site activation. Social media discussions were not covered in the provided notes.
How does Market Scanner analyse Estrella Immunopharma, Inc.?
Every analysis of Estrella Immunopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh ESLA.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.